Acute symptomatic seizure prevention with perampanel in moderate and severe traumatic brain injury: a retrospective comparison with levetiracetam
PER demonstrated a significant advantage over LEV in preventing ASS following moderate to severe TBI. Given its comparable psychiatric safety profile and functional outcomes, PER may be a promising therapeutic option for acute seizure prophylaxis in this population. However, further prospective studies with larger sample sizes are warranted to validate these findings.
Authors
- Shinji Kawabata (ORCID: https://orcid.org/0000-0001-5007-5279)
- Nakao Junzo
- K. Honda (ORCID: https://orcid.org/0000-0003-3868-7103)
- Akira Takasu
- Junji Hatakeyama (ORCID: https://orcid.org/0000-0003-2290-6965)
- Kohei Yoshimura (ORCID: https://orcid.org/0000-0003-4612-1820)
- Yu Amemiya
- Akihiro Kambara
- Hideki Kashiwagi (ORCID: https://orcid.org/0000-0003-3192-4065)
- Masahiko Wanibuchi (ORCID: https://orcid.org/0000-0002-1856-7123)
- Kazuma Yamakawa (ORCID: https://orcid.org/0000-0003-2999-4021)
- K Sakakibara
- Ryusuke Kotera
Institutions
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.3389/fneur.2025.1665997
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science